Improvements to tiny body-on-a-chip devices could lead to next-generation pre-clinical testing of drug toxicity
Researchers at Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) in Japan have designed a small ‘body-on-a-chip’ device that can test the side effects of drugs s on human cells. The device solves some issues with current, similar microfluidic devices and offers promise for the next generation of pre-clinical drug tests.
The Integrated Heart/Cancer on a Chip (iHCC) was used to test the toxicity of the anti-cancer drug doxorubicin on heart cells. The researchers, led by iCeMS’s Ken-ichiro Kamei, found that, while the drug itself was not toxic to heart cells, a metabolite of the drug resulting from its interaction with cancer cells was.
The device is smaller than a microscope glass slide. It contains six tiny chambers; every two are connected by microchannels with a series of port inlets and valves. A pneumatic pump controls movement of fluid through the channels. Every two chambers and their separate microchannel system constitute one test bed. Three test beds in the device allow for the introduction of minor changes in each bed to simultaneously compare results.
The team first tested doxorubicin’s effects on heart cells and liver cancer cells cultured separately in small wells. The drug had the expected anti-cancer effect on the cancer cells without causing damage to the heart cells.
They then ran the test using the iHCC device. Heart cells were placed in one chamber while liver cancer cells were placed in the other. Doxorubicin was introduced into a cell culture medium circulating through a closed-loop system of microchannels that connects the two chambers, mimicking the blood’s circulatory system. In this way, the drug flows unidirectionally in a continuous loop through both chambers.
The team found signs of toxicity in both cancer and heart cells. They hypothesized that a compound, doxorubicinol, which is a metabolic byproduct of doxorubicin interacting with cancer cells, was causing the toxic effect.
To test this, they added doxorubicinol to heart cells and liver cancer cells cultured separately in small wells. It was toxic to the heart cells but not to the cancer cells.
When doxorubicin alone is added to the liver cancer cells, the amount of doxorubicinol produced is too small to be toxic to the heart cells. The team believes this is because the amount of cell culture medium needed for the well-based tests dilutes the metabolite.
In contrast, when doxorubicin is introduced into the iHCC, the metabolite is not diluted when moving through the microchannel circulation system because a smaller volume of cell culture is needed. As a result, the drug does have a toxic effect on the heart cells via its metabolite.
The device requires further improvements, but the study demonstrates how this design concept could be used to investigate the toxic side effects of anti-cancer drugs on heart cells well before expensive clinical trials. The study was published in the journal Royal Society of Chemistry Advances.
Learn more: Next-generation drug testing on chips
The Latest on: Body-on-a-chip
- Eating Habits To Avoid if You Want a Lean Body, Say Dietitianson August 22, 2021 at 4:12 am
If you want to maintain a lean body and stay healthy, dietitians recommend that you steer clear of these eating habits.
- Salt lake civic body does patchwork road repairon August 21, 2021 at 12:33 pm
Residents and engineers of other government agencies are worried about the quality and longevity of BMC's work which refuses to lay a fresh layer of asphalt ...
- Three U.S. Senators Send Letter Asking Taiwan To Increase Automotive Chip Productionon August 20, 2021 at 2:04 pm
The letter, signed by Senators Gary Peters and Debbie Stabenow from Michigan and Senator Sherrod Brown of Ohio, praised Taiwan’s efforts so far but asked for more help as the automotive industry ...
- The Chip Shortage Strikes Again: Toyota to Cut Output by 40 Percenton August 20, 2021 at 11:41 am
Toyota is falling victim to the global chip shortage, and expects serious production cuts over the next few weeks.
- New analytical method visualizes cell functions in vasculature-on-a-chipon August 20, 2021 at 6:00 am
A microphysiological system (MPS), also known as an organ-on-a-chip, is a 3D organ construct using human cells that help reveal how organs respond to drugs and environmental stimuli.
- The World’s Largest Computer Chipon August 20, 2021 at 3:00 am
In the race to accelerate A.I., the Silicon Valley company Cerebras has landed on an unusual strategy: go big.
- AMD Share Price and News: AMD pulls back as chip sector trades loweron August 19, 2021 at 4:05 am
The chip sector pulled back as the industry awaited NVIDIA’s earnings. Chip maker GlobalFoundries has officially filed for its IPO. NASDAQ:AMD has had an interesting week, and it could have to do with ...
- Archer Materials didn’t disclose Australian patent body’s objectionson August 18, 2021 at 8:57 pm
Archer Materials topped a $700 million valuation after a 20-fold rise in two years, but did not disclose objections to its patent application by IP Australia.
- CSEM and USJC team up to develop an ultra-low-power chipon August 17, 2021 at 6:49 am
After five years of joint R&D, CSEM and Japanese multinational United Semiconductor Japan Co., Ltd. (USJC)* have developed an ultra-low-power system-on-chip that can be used to run smartphones, ...
- This 600-Rep Dumbbell Workout Packs a Full-Body Punchon August 16, 2021 at 2:55 am
But with an eye on movement selection and clever partitioning and pacing, the 600-rep workout below could be just the ticket for a metabolic, full-body dumbbell shootout that packs a muscle-building ...
via Google News and Bing News